Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum

Rhea-AI Summary

Acumen Pharmaceuticals (NASDAQ: ABOS), a biopharmaceutical company targeting Alzheimer's disease, will participate in the Needham Virtual Neuroscience Forum on March 15, 2023, at 10:00 a.m. ET. The company focuses on developing ACU193, a humanized monoclonal antibody aimed at combating toxic soluble amyloid beta oligomers, a key contributor to Alzheimer’s pathology. The live webcast can be accessed under the Investors tab on their website and will be available for 14 days post-event. Founded by researchers in amyloid beta oligomers, Acumen is advancing its Phase 1 clinical trial, INTERCEPT-AD, for early Alzheimer’s patients.

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 08, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Needham Virtual Neuroscience Forum on Wednesday, March 15, 2023 at 10:00 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 14 days.

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are primary triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.

Investors:
Alex Braun
abraun@acumenpharm.com

Media: 
AcumenPR@westwicke.com

FAQ

What is Acumen Pharmaceuticals' focus for Alzheimer's treatment?

Acumen Pharmaceuticals is focused on developing ACU193, a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers, which are implicated in Alzheimer's disease.

When will Acumen Pharmaceuticals present at the Needham Virtual Neuroscience Forum?

Acumen Pharmaceuticals will present at the Needham Virtual Neuroscience Forum on March 15, 2023, at 10:00 a.m. ET.

How can I access the Acumen Pharmaceuticals webcast?

The live webcast can be accessed under the Investors tab on Acumen Pharmaceuticals' website and will be available for 14 days following the event.

What is the current clinical trial status for ACU193?

ACU193 is currently undergoing a Phase 1 clinical trial known as INTERCEPT-AD, focusing on early Alzheimer’s disease patients.

Who are the scientific founders of Acumen Pharmaceuticals?

The scientific founders of Acumen Pharmaceuticals are researchers who pioneered studies on toxic soluble amyloid beta oligomers, which are linked to Alzheimer's disease pathology.